PriceSensitive

Anteris Technologies (ASX:AVR) enters trading halt

The Market Online Deal Room
ASX:AVR      MCAP $422.8M
01 March 2022 14:53 (AEST)
Anteris Technologies (ASX:AVR) - Chief Executive, Wayne Paterson

Source: Anteris Technologies (Twitter)

Anteris Technologies (AVR) has started the week in a trading halt ahead of an upcoming capital raise.

So far, it is unknown how much the company is aiming to raise or where the funds will be spent.

AVR shares will be paused until Thursday, March 3, or when further details about the raise are released to the market.

Anteris is an Australian based structural heart company that is developing solutions that help healthcare professionals.

Earlier this year, the company reported “excellent” results from the first-in-human trial of its DurAVR replacement heart valve.

Anteris surgically installed the valve in five patients of a 10-patient trial, with positive results recorded at the 30-day follow up point.

Chief Medical Officer Chris Meduri, who led the study, said the exercise performance indicated early improvements in the quality of life in patients who received the DurAVR valve.

On the market, Anteris last traded at $18.67 per share.

Related News